Trial of topical formulation of diacerein (AC-201)

Trial Profile

Trial of topical formulation of diacerein (AC-201)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Diacerein (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions
  • Sponsors TWi Biotechnology
  • Most Recent Events

    • 03 Oct 2016 According to Castle Creek Pharmaceuticals media release status changed from planning to completed.
    • 24 Oct 2014 New trial record
    • 21 Oct 2014 Diacerein has been designated as an Orphan Drug by the US FDA for the treatment of epidermolysis bullosa, and TWi Biotechnology is planning to proceed with this trial in the near future, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top